### Edgar Filing: BIO BLAST PHARMA LTD. - Form 6-K

BIO BLAST PHARMA LTD. Form 6-K June 09, 2016
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: June 2016
Commission file number: 001-36578
BIOBLAST PHARMA LTD.
(Translation of registrant's name into English)
37 Dereh Menechem Begin St., 15 <sup>th</sup> Floor

Tel Aviv 6522042 Israel

(Address of principal executive offices)

# Edgar Filing: BIO BLAST PHARMA LTD. - Form 6-K

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F "
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):

#### **CONTENTS**

This Report of Foreign Private Issuer on Form 6-K of the Registrant consists of the press release issued by the Registrant on June 9, 2016, announcing corporate updates, which is attached hereto as Exhibit 99.1.

The first through the fourth paragraphs, the first sentence of the tenth paragraph and the eleventh paragraph of the Registrant's press release attached to this Form 6-K are incorporated by reference into the registration statement on Form F-3 (File No. 333-206032) and the registration statements on Form S-8 (File No. 333-203114 and 333-210459) of the Registrant, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

#### Exhibit No.

99.1 Press Release issued by BioBlast Pharma Ltd. on June 9, 2016, announcing corporate updates.

## Edgar Filing: BIO BLAST PHARMA LTD. - Form 6-K

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BioBlast Pharma Ltd. (Registrant)

By /s/ Fredric Price Name: Fredric Price Executive Chairman

Date: June 9, 2016